GLP-1 RA on Liver OMICS in MASLD

Withdrawn before enrolling

Conditions studied: NAFLD, Diabetes, Obesity

In brief

In patients with type II diabetes mellitus (T2DM) and obesity, an excess plasma-free fatty acid is found with an associated increased lipid accumulation in adipocytes and liver tissue. Lipid droplet accumulation in the hepatocytes is an initial step in the development of metabolic dysfunction associated steatotic liver disease (MASLD. Insulin resistance, which is associated with T2DM, mediates the inflammation of these lipids, resulting in the progression of MASLD to metabolic dysfunction associated steatotic hepatitis (MASH). Hence, in T2DM, obesity, and MASLD, changes in the lipid profile occur, and they are interrelated. In this study, we aim to assess improvement in the lipidomic, its associated metabolic changes and evaluate the co-regulated genes in the liver tissue among patients with MASLD with intervention with GLP-1 RA, which has shown to benefit T2DM and obesity.

Key facts

Study ID

NCT06982378

Run by

Medical College of Wisconsin

People needed

0

Starts

2026-07-01

Expected to finish

2026-07-09

Last updated by the study team

2026-07-13

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• known diagnosis of MASLD by histology, also have diabetes/ obesity
• on treatment with GLP-1 RA at stable dose

You may not qualify if…

• unable to have a liver biopsy, recent change in medication for diabetes or hyperlipidemia
• on immunosuppression, liver or kidney transplant
• pregnancy

Where it is running

• Froedtert Hospital — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.